User:Mr. Ibrahem/Tralokinumab
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL-13 |
| Clinical data | |
| Trade names | Adtralza, Adbry |
| Other names | CAT-354, tralokinumab-ldrm |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Subcutaneous |
| Legal status | |
| Legal status | |
| Chemical and physical data | |
| Formula | C6374H9822N1698O2014S44 |
| Molar mass | 143875.20 g·mol−1 |
  (what is this?) (verify) | |
Tralokinumab, sold under the brand names Adtralza and Adbry, is a medication used to treat atopic dermatitis.[4] Specifically it is used for moderate to severe disease which is not controlled by medication applied to the skin.[2][3] It is given by injection under the skin.[3]
Common side effects include upper respiratory tract infections such as the common cold, reactions at the injection site, and eye pain and redness.[4] Other side effects may include anaphylaxis and angioedema.[5] While there is no evidence of harm in pregnancy, such use has not been well studied.[5] It is a monoclonal antibody which blacks the activity of cytokine interleukin 13.[4][6]
Tralokinumab was approved for medical use in Europe, the United States, and the United Kingdom in 2021.[2][4][3] In the United Kingdom it costs the NHS about £1070 for 600 mg as of 2022.[7] This amount in the United States costs about 3,300 USD.[8]
References[edit]
- ^ "Summary Basis of Decision (SBD) for Adtralza". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
- ^ a b c "Adtralza 150 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 5 July 2021. Archived from the original on 9 July 2021. Retrieved 9 July 2021.
- ^ a b c d e "Adbry- tralokinumab-ldrm injection, solution". DailyMed. Archived from the original on 13 January 2022. Retrieved 13 January 2022.
- ^ a b c d e f g "Adtralza EPAR". European Medicines Agency (EMA). 20 April 2021. Archived from the original on 29 June 2021. Retrieved 9 July 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Tralokinumab Monograph for Professionals". Drugs.com. Retrieved 23 October 2022.
- ^ Kopf M, Bachmann MF, Marsland BJ (September 2010). "Averting inflammation by targeting the cytokine environment". Nature Reviews. Drug Discovery. 9 (9): 703–18. doi:10.1038/nrd2805. PMID 20811382. S2CID 23769909.
- ^ "Tralokinumab". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 15 February 2022. Retrieved 23 October 2022.
- ^ "Tralokinumab-Ldrm". Goodrx.com. Archived from the original on 23 October 2022. Retrieved 23 October 2022.